BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24859762)

  • 1. Aromatic diacylhydrazine derivatives as a new class of polo-like kinase 1 (PLK1) inhibitors.
    Sun J; Lv PC; Guo FJ; Wang XY; Xiao-Han ; Zhang Y; Sheng GH; Qian SS; Zhu HL
    Eur J Med Chem; 2014 Jun; 81():420-6. PubMed ID: 24859762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.
    Chen DX; Huang J; Liu M; Xu YG; Jiang C
    Arch Pharm (Weinheim); 2015 Jan; 348(1):2-9. PubMed ID: 25430493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
    Chen S; Bartkovitz D; Cai J; Chen Y; Chen Z; Chu XJ; Le K; Le NT; Luk KC; Mischke S; Naderi-Oboodi G; Boylan JF; Nevins T; Qing W; Chen Y; Wovkulich PM
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1247-50. PubMed ID: 22172702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
    Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G
    Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
    Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of nitroimidazole-oxime derivatives targeting the polo-box domain of polo-like kinase 1.
    Sun J; Liu HY; Xu RF; Zhu HL
    Bioorg Med Chem; 2017 Dec; 25(24):6581-6588. PubMed ID: 29100732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.
    Zhang Q; Xia Z; Mitten MJ; Lasko LM; Klinghofer V; Bouska J; Johnson EF; Penning TD; Luo Y; Giranda VL; Shoemaker AR; Stewart KD; Djuric SW; Vasudevan A
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7615-22. PubMed ID: 23103095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
    Shan HM; Shi Y; Quan J
    ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design and SAR development of novel selective polo-like kinase 1 inhibitors having the tetrahydropteridin scaffold.
    Lv X; Yang X; Zhan MM; Cao P; Zheng S; Peng R; Han J; Xie Z; Tu Z; Liao C
    Eur J Med Chem; 2019 Dec; 184():111769. PubMed ID: 31629162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
    Lu S; Sun SL; Liu HC; Chen YD; Yuan HL; Gao YP; Yang P; Lu T
    Chem Biol Drug Des; 2012 Aug; 80(2):328-39. PubMed ID: 22583481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
    Mita Y; Noguchi-Yachide T; Ishikawa M; Hashimoto Y
    Bioorg Med Chem; 2013 Feb; 21(3):608-17. PubMed ID: 23276450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.
    Rheault TR; Donaldson KH; Badiang-Alberti JG; Davis-Ward RG; Andrews CW; Bambal R; Jackson JR; Cheung M
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4587-92. PubMed ID: 20594842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of naphthalimide-derivatives as novel PBD-targeted polo-like kinase 1 inhibitors with efficacy in drug-resistant lung cancer cells.
    Li P; Li Y; Ma X; Li L; Zeng S; Peng Y; Liang H; Zhang G
    Eur J Med Chem; 2024 May; 271():116416. PubMed ID: 38657480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
    Beria I; Bossi RT; Brasca MG; Caruso M; Ceccarelli W; Fachin G; Fasolini M; Forte B; Fiorentini F; Pesenti E; Pezzetta D; Posteri H; Scolaro A; Re Depaolini S; Valsasina B
    Bioorg Med Chem Lett; 2011 May; 21(10):2969-74. PubMed ID: 21470862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.
    Pezuk JA; Brassesco MS; Ramos PMM; Scrideli CA; Tone LG
    Anticancer Agents Med Chem; 2017; 17(9):1278-1291. PubMed ID: 28270075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphopeptides with improved cellular uptake properties as ligands for the polo-box domain of polo-like kinase 1.
    Richter S; Neundorf I; Loebner K; Gräber M; Berg T; Bergmann R; Steinbach J; Pietzsch J; Wuest F
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4686-9. PubMed ID: 21778054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells.
    Chapagai D; Ramamoorthy G; Varghese J; Nurmemmedov E; McInnes C; Wyatt MD
    J Med Chem; 2021 Jul; 64(14):9916-9925. PubMed ID: 34210138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
    Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
    Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.
    Craig SN; Baxter M; Chapagai D; Stafford JM; Nurmemmedov E; Altomare D; Wyatt MD; McInnes C
    Eur J Med Chem; 2022 Jan; 227():113926. PubMed ID: 34735919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.